Linked Life Data

20847284

Source:http://linkedlifedata.com/resource/pubmed/id/20847284

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-11-4
pubmed:abstractText
Nitric oxide (NO), which is derived from endothelial NO synthase (eNOS), provides crucial signals for angiogenesis in the tumor microenvironment. Tetrahydrobiopterin (BH4) is an absolute requirement for eNOS activity. In this study, we investigated whether this activation is both maintained by a wild-type Ras/phosphatidylinositol 3-kinase (PI3K)/Akt-positive feedback loop in endothelial cells and affects tumor angiogenesis. We found that supplementation of BH4 (via the pterin salvage pathway with Sep) increased Akt/eNOS phosphorylation in both human eNOS-transfected COS-7 cells and endothelial cells concomitant with increases in NO production, cell proliferation, migration, and tube formation. This augmentation was abrogated by a PI3K inhibitor. Sepiapterin (Sep) also increased GTP-bound wild-type Ras and PI3K/Akt/eNOS activation, which was prevented by the eNOS inhibitor, N?-Nitro-L-arginine methyl ester (L-NAME). Furthermore, expression of GTP cyclohydrolase I (the rate-limiting enzyme in de novo BH4 synthesis) under doxycycline control potentiated in vivo tumorigenesis, tumor cell proliferation, as well as angiogenesis. Conversely, both switching off GTP cyclohydrolase I expression as well as inhibiting its enzymatic activity significantly decreased eNOS expression and tumor vascularization. This study demonstrates an important role for BH4 synthesis in angiogenesis by the activation of eNOS for NO production, which is maintained by a PI3K/Akt-positive feedback loop through effects on wild-type Ras in endothelial cells. Our findings suggest that BH4 synthesis may be a rational target for antiangiogenesis therapy for tumors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1525-2191
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
177
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2671-80
pubmed:dateRevised
2011-11-1
pubmed:meshHeading
pubmed-meshheading:20847284-Animals, pubmed-meshheading:20847284-Biopterin, pubmed-meshheading:20847284-COS Cells, pubmed-meshheading:20847284-Cell Movement, pubmed-meshheading:20847284-Cell Proliferation, pubmed-meshheading:20847284-Cercopithecus aethiops, pubmed-meshheading:20847284-Enzyme Activation, pubmed-meshheading:20847284-Humans, pubmed-meshheading:20847284-Mice, pubmed-meshheading:20847284-NIH 3T3 Cells, pubmed-meshheading:20847284-Neovascularization, Pathologic, pubmed-meshheading:20847284-Nitric Oxide, pubmed-meshheading:20847284-Nitric Oxide Synthase Type III, pubmed-meshheading:20847284-Phosphatidylinositol 3-Kinases, pubmed-meshheading:20847284-Proto-Oncogene Proteins c-akt, pubmed-meshheading:20847284-Pterins, pubmed-meshheading:20847284-Signal Transduction, pubmed-meshheading:20847284-Tumor Microenvironment, pubmed-meshheading:20847284-ras Proteins
pubmed:year
2010
pubmed:articleTitle
Roles of tetrahydrobiopterin in promoting tumor angiogenesis.
pubmed:affiliation
Department of Clinical Pharmacology, University of Oxford, John Radcliffe Hospital, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't